LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Ultra-Fast Test for COVID-19 Antibodies Uses AI to Analyze and Confirm Results in Less than Five Minutes

By LabMedica International staff writers
Posted on 03 May 2021
Print article
Image: The University of Utah, ARUP Laboratories and Techcyte Inc. have formed a partnership to develop the NanoSpot (Photo courtesy of University of Utah)
Image: The University of Utah, ARUP Laboratories and Techcyte Inc. have formed a partnership to develop the NanoSpot (Photo courtesy of University of Utah)
A new less than five-minute, easy-to-administer SARS-CoV-2 antibody test is estimated to be significantly less expensive to manufacture, creating the potential for the test to be considerably more affordable than currently available tests and making it possible to extend the test to every corner of the world.

The University of Utah (Salt Lake City, UT, USA), ARUP Laboratories (Salt Lake City, UT, USA) and Techcyte Inc. (Orem, UT, USA) have formed a partnership to develop the NanoSpot. AI rapid COVID-19 antibody test. After the test has been completed, the person administering the test takes a picture of the test card using a mobile phone. The image is transmitted to Techcyte, a developer of artificial intelligence (AI)-based image analysis solutions for the diagnostics industry, for analysis using the company’s AI-based image analysis tool.

The patent-pending NanoSpot.AI is performed on a spot of blood obtained through a finger prick. All NanoSpot.AI test components are provided in a self-contained kit. The person administering the test places droplets of blood in three small spots on a ready-to-use card. One of the spots displays the test result while the other two confirm the test was properly run. Antibodies against SARS-CoV-2 are quickly apparent because the blood spot begins to separate within seconds when the test result is positive. To ensure accurate results, the person administering the test uses a mobile phone to take a photograph of the card, which is then transmitted to Techcyte for analysis using the company’s AI-based image analysis tool. Techcyte. The test could be used around the globe to help prioritize who should receive SARS-CoV-2 vaccinations, or to easily and quickly detect whether individuals have some immunity against COVID-19 for travel or immigration purposes. Clinical studies validating NanoSpot.AI are currently underway. The assay can be easily adapted to test for antibodies to SARS-CoV-2 variants as new mutations emerge. The test can be viewed as a platform because it and the AI can be developed to test for antibodies against other viruses.

“Our platform breaks each blood spot into thousands of features that the AI uses to statistically determine which specimens are positive for SARS-CoV-2 antibodies,” said Techcyte CEO Ben Cahoon.

“Other antibody tests are available and are very good, but it takes time to get test results back and they’re relatively expensive,” said Hans Haecker, MD, PhD, who co-developed NanoSpot.AI. “Based on what we know so far, we believe NanoSpot.AI checks all the boxes. “Because it is simple, fast, and very affordable, it can be done anywhere without specialized equipment, creating the potential for us to have an impact on human health around the world.”

Related Links:
The University of Utah
ARUP Laboratories
Techcyte Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more